ALIVE Israel HealthTech Fund

ALIVE Israel HealthTech Fund is a mid-to-late stage venture capital firm specializing in investments in Israeli health technology companies. The fund leverages an exclusive ecosystem of strategic partners, including leading hospital chains, health maintenance organizations (HMOs), and financial institutions, to support and accelerate the clinical and commercial expansion of its portfolio companies. This collaborative approach provides portfolio companies with access to invaluable resources such as clinical infrastructures, key opinion leaders (KOLs), big data, domain experts, and financial backing, facilitating a comprehensive understanding of clinical workflows and procedures to ensure product-market fit under challenging health economics.

The fund's investment strategy focuses on promising mid-to-late stage companies developing innovative platform technologies with the potential to become the gold standard in various medical disciplines. Key areas of interest include medical devices, diagnostics, digital health, healthcare IT, and artificial intelligence applications in healthcare. ALIVE seeks highly fundable companies with strong management teams, broad intellectual property protection, and a proven track record of execution, aiming to benefit from the strategic synergies offered by its ecosystem.

Since its inception in 2020, ALIVE Israel HealthTech Fund has made several investments in companies such as Medisafe, Innovalve, Cynerio, Beyeonics Vision, Beyeonics Surgical, Nevia Bio, OncoHost, Navina, Wisdo, Append Medical, and Vessi Medical. The fund has also achieved notable exits, including the acquisition of Innovalve by Edwards Lifesciences and Cynerio by Axonius. With a combined experience of over 60 years, the ALIVE team is dedicated to driving health technology from business plan to business success, optimizing value creation across all stages of the investment journey, from clinical trials and FDA approvals to market validation and product adoption, culminating in successful entries into capital markets and strategic deals.